Competition aims to incentivize vaccine development breakthrough
At our annual conference in Belfast, held last month, Dr Jeremy Salt, Chief Scientific Officer from the Global Alliance for Livestock Veterinary Medicines (GALVmed), presented details of the new Brucellosis Vaccine Prize Competition.
A global competition funded by AgResults and implemented by GALVmed, it invites vaccine developers to submit their proposals for – and ultimately develop – a suitable vaccine that is efficacious, safe and viable for use against Brucella melitensis in small ruminants across the developing world. By entering the competition, ‘Solvers’ have the chance to win a share of the US $30 million prize fund.
The competition is open to any organization that has the ability to develop vaccines. That may include animal health, biotech and pharmaceutical companies, as well as academic and research institutions. Organizations are welcome to partner with third parties if they need additional expertise or capabilities.
Peter Jeffries, CEO of GALVmed, said the competition represents an exciting opportunity for animal health innovators around the world to help meet the real world needs of 600 million people in developing countries whose livelihoods depend on livestock.
Click here to see Peter Jeffries talk about the purpose and nature of the competition – the first of its kind in animal health.
Applications for Phase 1 are open until November 2017.
Do you think you have a winning idea? Click here to learn more and apply: http://www.brucellosisvaccine.org/